Anemia

Optimal Vitamin C Dose for Anemia in Hemodialysis Patients Unclear

Optimal Vitamin C Dose for Anemia in Hemodialysis Patients Unclear

By

Pending future research, patients should avoid taking more than 120 mg per day.

Cinacalcet Possibly Improves Anemia

Cinacalcet Possibly Improves Anemia

By

SHPT patients who received 6 months of cinacalcet treatment had a 10% increase in the odds of reaching target hemoglobin levels.

Dialysis Patient Outcomes Not Worse After Bundling, ESA Label Changes

Dialysis Patient Outcomes Not Worse After Bundling, ESA Label Changes

By

Study finds no increased risk of major adverse cardiovascular events and death.

Factors Linked to Worse Post-Surgical Kidney Function ID'd

Factors Linked to Worse Post-Surgical Kidney Function ID'd

Factors including low preoperative mean arterial BP tied to increases in eGFR, kidney injury.

Lower ESA Use for Anemia Linked to Maintenance IV Iron

Lower ESA Use for Anemia Linked to Maintenance IV Iron

By

Management strategy also is associated with reduced mortality risk, but not achievement of hemoglobin targets.

High CRP Ups Kidney Failure Risk in Diabetic CKD Patients With Anemia

High CRP Ups Kidney Failure Risk in Diabetic CKD Patients With Anemia

By

End-stage renal disease is 32% more likely to develop in patients with C-reactive protein levels of 6.9 mg/L or higher vs 3.0 mg/L or lower.

Hypogonadism in Male HD Patients Linked to Poor ESA Response

Hypogonadism in Male HD Patients Linked to Poor ESA Response

By

Other risk factors include reduced muscle mass and lower levels of physical activity.

Hemodialysis Patient Hyporesponsiveness to ESAs Ups Death Risk

Hemodialysis Patient Hyporesponsiveness to ESAs Ups Death Risk

By

A recent study resulted in a new definition of less-than-optimal response to erythropoiesis-stimulating agents.

Most Cost-Effective Hb Target in Anemic CKD Patients Identified

Most Cost-Effective Hb Target in Anemic CKD Patients Identified

By

A hemoglobin level of 10.5 g/dL offers the optimal balance of cost and quality adjusted life years, researchers conclude.

Diabetes May Increase Anemia Risk in CKD Patients

Diabetes May Increase Anemia Risk in CKD Patients

By

The odds of developing anemia were 2-fold greater among patients with than without diabetes mellitus.

Anemic CKD Patients Have Lower Health-Related Quality of Life

Anemic CKD Patients Have Lower Health-Related Quality of Life

By

Anemia was associated with impaired activity levels at CKD stages 3, 4, and dialysis.

ESA Resistance Linked to Vitamin B6 Treatment

ESA Resistance Linked to Vitamin B6 Treatment

By

IV administration of vitamin B6 did not improve anemia or abnormal bone metabolism over 6 months.

High-Dose ESAs Found to Increase Cancer Risk in Dialysis Patients

High-Dose ESAs Found to Increase Cancer Risk in Dialysis Patients

By

Average weekly doses greater than 70 µg/week was associated with a 77% increased risk of cancer compared with no ESA exposure.

ESA-Resistance Linked to Early Death

ESA-Resistance Linked to Early Death

By

A high erythropoietin resistance index was associated with triple the risk for death from any cause.

Is Giving Small Iron Doses Per Dialysis Session Better for Patients?

Is Giving Small Iron Doses Per Dialysis Session Better for Patients?

By

Patients provided small doses of intravenous iron per treatment achieved higher hemoglobin levels than patients receiving weekly iron.

Hepatic Iron Overload May Be Common Before Dialysis

Hepatic Iron Overload May Be Common Before Dialysis

By

In a small study, 82% of patients had iron overload prior to hemodialysis initiation.

Anemia Prevalence, Treatment in Non-Dialysis CKD Varies by Country

Anemia Prevalence, Treatment in Non-Dialysis CKD Varies by Country

By

Less than half of anemic patients were prescribed ESAs or iron in the US and France, and a high percentage overall did not have iron indices measured.

ESA Doses Lower Among Dialysis Patients at Higher Elevations

ESA Doses Lower Among Dialysis Patients at Higher Elevations

By

Investigators find that the normalized mean ESA dose decreases as patients' elevation of residence increases.

Higher Conversion Ratio for Epoetin Beta to Darbepoetin Alfa

Higher Conversion Ratio for Epoetin Beta to Darbepoetin Alfa

By

Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin.

Anemia Risk Factors in Peritoneal Dialysis Patients ID'd

Anemia Risk Factors in Peritoneal Dialysis Patients ID'd

By

New findings implicate transferrin saturation and nutritional status assessed by albumin.

TRT Found to Reduce Anemia in Hypogonadal Men

TRT Found to Reduce Anemia in Hypogonadal Men

By

After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.

Managing Anemia in Cancer Patients With CKD

Managing Anemia in Cancer Patients With CKD

A summary of Dr. Jeffrey S. Berns' presentation that will be given at the National Kidney Foundation's 2016 Spring Clinical Meetings in Boston, MA.

Ferritin Levels Rising in Hemodialysis Patients

Ferritin Levels Rising in Hemodialysis Patients

By

Trend is independent of intravenous iron use and exposure to erythropoiesis-stimulating agents.

CERA Safe, Effective in Patient Subgroups

CERA Safe, Effective in Patient Subgroups

By

No new adverse events observed in patients with underlying cardiovascular risk factors who switched to continuous erythropoietin receptor activator.

Platelet/Lymphocyte Ratio May Predict ESA Resistance

Platelet/Lymphocyte Ratio May Predict ESA Resistance

By

Greater hyporesponsiveness to erythropoiesis-stimulating agents was associated with increased PLR ratios.

Dialysis Bundling, ESA Labeling Changes Did Not Increase Mortality

Dialysis Bundling, ESA Labeling Changes Did Not Increase Mortality

By

Observed rates of all-cause and cardiovascular mortality and myocardial infarction were consistent with expected rates, study shows.

Good Residual Renal Function Improves HD Patient Outcomes

Good Residual Renal Function Improves HD Patient Outcomes

By

Researchers observe significantly higher levels of albumin and hemoglobin and better calcium and phosphate metabolism.

ESAs Don't Improve Anemia Patients' Quality of Life

ESAs Don't Improve Anemia Patients' Quality of Life

Based on effect of erythropoietin-stimulating agents for higher hemoglobin targets.

ESRD Anemia Responds to Investigational Oral Drug

ESRD Anemia Responds to Investigational Oral Drug

By

In a phase 2 trial, roxadustat maintained hemoglobin levels over 19 weeks as well as epoetin alfa.

IV Iron Safe for Treating Anemia in Acute Kidney Injury Patients

IV Iron Safe for Treating Anemia in Acute Kidney Injury Patients

By

In a case-control study, the treatment did not adversely affect mortality or recovery from AKI.

Sign Up for Free e-newsletters